Literature DB >> 20882258

Gene expression changes in multiple sclerosis relapse suggest activation of T and non-T cells.

J William Lindsey1, Sandeep K Agarwal, Filemon K Tan.   

Abstract

A defining feature of multiple sclerosis (MS) is the occurrence of clinical relapses separated by periods of clinical stability. Better understanding of the events underlying clinical relapse might suggest new approaches to treatment. The objective of this study was to measure changes in the expression of RNA in the blood during relapse. We used microarrays to measure mRNA expression in paired samples from 14 MS patients during clinical relapse and while stable. Seventy-one transcripts changed expression at the P < 0.001 significance level. The most notable finding was decreased expression of transcripts with regulatory function, expressed primarily in non-T cells. These decreased transcripts included the interleukin-1 receptor antagonist, which had a corresponding decrease in the protein concentration in serum. Transcripts with increased expression were expressed primarily in T cells. Pathways analysis suggested involvement of the cytokine network, coagulation and complement cascades, IL-10 signaling and NF-κB signaling. We conclude that there are alterations of mRNA expression in both T cells and non-T cells during MS relapse.

Entities:  

Mesh:

Year:  2010        PMID: 20882258      PMCID: PMC3022990          DOI: 10.2119/molmed.2010.00071

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  31 in total

1.  Microarray detection of E2F pathway activation and other targets in multiple sclerosis peripheral blood mononuclear cells.

Authors:  Antonio H Iglesias; Sandra Camelo; Daehee Hwang; Raul Villanueva; George Stephanopoulos; Fernando Dangond
Journal:  J Neuroimmunol       Date:  2004-05       Impact factor: 3.478

Review 2.  Not-so-sweet sixteen: the role of IL-16 in infectious and immune-mediated inflammatory diseases.

Authors:  William G Glass; Robert T Sarisky; Alfred M Del Vecchio
Journal:  J Interferon Cytokine Res       Date:  2006-08       Impact factor: 2.607

3.  Impaired expression of peripheral blood apoptotic-related gene transcripts in acute multiple sclerosis relapse.

Authors:  Anat Achiron; Anna Feldman; Mathilda Mandel; Michael Gurevich
Journal:  Ann N Y Acad Sci       Date:  2007-06       Impact factor: 5.691

4.  Induction of serum soluble tumor necrosis factor receptor II (sTNF-RII) and interleukin-1 receptor antagonist (IL-1ra) by interferon beta-1b in patients with progressive multiple sclerosis.

Authors:  Manuel Comabella; E Julià; M Tintoré; L Brieva; N Téllez; J Río; C López; A Rovira; X Montalban
Journal:  J Neurol       Date:  2008-05-20       Impact factor: 4.849

5.  Blood transcriptional signatures of multiple sclerosis: unique gene expression of disease activity.

Authors:  Anat Achiron; Michael Gurevich; Nir Friedman; Naftali Kaminski; Mathilda Mandel
Journal:  Ann Neurol       Date:  2004-03       Impact factor: 10.422

6.  Changes of serum complement and of circulating immune complexes in patients with multiple sclerosis.

Authors:  M Cojocaru; A Serbănescu; I M Cojocaru
Journal:  Rom J Intern Med       Date:  1993 Apr-Jun

7.  Relapses in multiple sclerosis are associated with increased CD8+ T-cell mediated cytotoxicity in CSF.

Authors:  Clas Malmeström; Jan Lycke; Sara Haghighi; Oluf Andersen; Lena Carlsson; Hans Wadenvik; Bob Olsson
Journal:  J Neuroimmunol       Date:  2008-04-08       Impact factor: 3.478

8.  Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1beta in human monocytes and multiple sclerosis.

Authors:  Danielle Burger; Nicolas Molnarfi; Martin S Weber; Karim J Brandt; Mahdia Benkhoucha; Lyssia Gruaz; Michel Chofflon; Scott S Zamvil; Patrice H Lalive
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-02       Impact factor: 11.205

9.  A random variance model for detection of differential gene expression in small microarray experiments.

Authors:  George W Wright; Richard M Simon
Journal:  Bioinformatics       Date:  2003-12-12       Impact factor: 6.937

10.  Molecular network analysis of T-cell transcriptome suggests aberrant regulation of gene expression by NF-kappaB as a biomarker for relapse of multiple sclerosis.

Authors:  Jun-ichi Satoh; Tamako Misawa; Hiroko Tabunoki; Takashi Yamamura
Journal:  Dis Markers       Date:  2008       Impact factor: 3.434

View more
  5 in total

1.  Immune and Epstein-Barr virus gene expression in cerebrospinal fluid and peripheral blood mononuclear cells from patients with relapsing-remitting multiple sclerosis.

Authors:  Caterina Veroni; Fabiana Marnetto; Letizia Granieri; Antonio Bertolotto; Clara Ballerini; Anna Maria Repice; Lucia Schirru; Giancarlo Coghe; Eleonora Cocco; Eleni Anastasiadou; Maria Puopolo; Francesca Aloisi
Journal:  J Neuroinflammation       Date:  2015-07-14       Impact factor: 8.322

2.  Changes in expression profiles of internal jugular vein wall and plasma protein levels in multiple sclerosis.

Authors:  Giovanna Marchetti; Nicole Ziliotto; Silvia Meneghetti; Marcello Baroni; Barbara Lunghi; Erica Menegatti; Massimo Pedriali; Fabrizio Salvi; Ilaria Bartolomei; Sofia Straudi; Fabio Manfredini; Rebecca Voltan; Nino Basaglia; Francesco Mascoli; Paolo Zamboni; Francesco Bernardi
Journal:  Mol Med       Date:  2018-08-09       Impact factor: 6.354

3.  Methylglyoxal-Derived Advanced Glycation Endproducts Accumulate in Multiple Sclerosis Lesions.

Authors:  Suzan Wetzels; Tim Vanmierlo; Jean L J M Scheijen; Jack van Horssen; Sandra Amor; Veerle Somers; Casper G Schalkwijk; Jerome J A Hendriks; Kristiaan Wouters
Journal:  Front Immunol       Date:  2019-04-24       Impact factor: 7.561

Review 4.  Nuclear Factor κB (NF-κB)-Mediated Inflammation in Multiple Sclerosis.

Authors:  Yifan Zhou; Chunping Cui; Xiaoyu Ma; Wenjing Luo; Song Guo Zheng; Wei Qiu
Journal:  Front Immunol       Date:  2020-03-24       Impact factor: 7.561

5.  In Silico and In Vivo Analysis of IL37 in Multiple Sclerosis Reveals Its Probable Homeostatic Role on the Clinical Activity, Disability, and Treatment with Fingolimod.

Authors:  Eugenio Cavalli; Emanuela Mazzon; Maria Sofia Basile; Santa Mammana; Manuela Pennisi; Paolo Fagone; Reni Kalfin; Vanja Martinovic; Jovana Ivanovic; Marko Andabaka; Sarlota Mesaros; Tatjana Pekmezovic; Jelena Drulovic; Ferdinando Nicoletti; Maria Cristina Petralia
Journal:  Molecules       Date:  2019-12-19       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.